Gliatech (GLIA) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Gliatech (GLIA)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: biowa who wrote (1485)	3/12/2000
From: RWReeves	Read Replies (1) of 2001

<Note also AVAN's complement inhibitor program, partially partnered and also in the clinic. > Is this the program AVAN got from VRI/T-Cell? I recall these programs from earlier times, and partner was SKB. Have not followed to see how it faired in trials but looked good in Phase I/II I recall. Looked like a promising program. Late great T-Cell: informagen.com Basic complement inhibitor patent set. There are more later I believe also. patent.womplex.ibm.com From the AVAN 10-K "AVANT started the complement program in 1988. From 1989 through 1994, TP10 was under development in a joint program with SmithKline Beecham, p.l.c. ("SmithKline") and Yamanouchi Pharmaceutical Co. ("Yamanouchi"). During 1994, AVANT and SmithKline negotiated various amendments to the agreement and, in February 1995, the two companies agreed to a mutual termination " Probably someone on the AVAN thread knows the whole story. RWR

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next